Skip to content

Psilocybin for addiction: all studies

Page 2 of 19: studies 11 to 20 of 183, newest first. Back to the psilocybin for addiction overview

Research

Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility

Frontiers in Neuroscience March 23, 2026 Malkanthi Evans, Andrew Charrette

While the limitations of existing treatment options have spurred investigations into the applicability of psychedelic therapies for chronic and treatment-resistant psychological disorders, there remain significant unresolved issues pertaining to how these treatments should be regulated and the implementation of an ethical framework for their widespread delivery in practice.Research...

Review of: "Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review"

February 1, 2026 Carlton J Spotswood

Things to consider: .In the intro: "The so-called magic mushrooms from which psychedelics are extracted were traditionally absorbed by South-American peoples." This is clunky and I suspect it is due to translation errors; consider changing it. .In the intro: "In 1998, Dr. Heffter nally discovered a psychedelic active substance and named it mescaline." This was rst published in 1897, not 1998....

Psychedelics in psychiatric treatment: a literature review

Quality in Sport January 26, 2026 Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong et al.

Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use...

THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS

International Journal of Innovative Technologies in Social Science January 23, 2026 Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg et al.

The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e.g., SSRIs), has precipitated a critical need for novel therapeutic paradigms. This article presents a comprehensive systematic review of the so-called "Psychedelic Renaissance," focusing on the clinical resurgence of classical serotonergic...

Can Psychedelics help with Alcohol Use Disorder (AUD): For now, the data says no.

Science academique 2026 Kenneth Blum, Kai-Uwe Lewandrowski, Morgan P Lorio et al.

The aim of this perspective article is to evaluate the potential of Psychedelics in the management of Alcohol Use Disorder (AUD) vis-a-vis pre-existing therapeutic modalities and to elucidate practical directions for policy in AUD Addiction medicine, supported by scientific evidence, while prioritizing safety and accessibility. We performed a narrative synthesis of past and current literature...

Psychological Support in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: A Scoping Review Protocol

Open MIND 2026 Amin Nazmuddin Mohammadi, Christine Wekerle

Alcohol use disorder (AUD) is a prevalent and chronic psychiatric condition characterized by impaired control over alcohol use, compulsive consumption, and high rates of relapse (Grant et al., 2015; Kurihara, 2023). Despite the availability of pharmacological and psychosocial interventions, treatment outcomes remain suboptimal, with substantial rates of non-response and relapse (Lohoff, 2022;...

High hopes? Precision psychedelic addiction medicine

Spiral (Imperial College London) December 30, 2025 Rayyan Zafar

Despite decades of neuroscience research and significant investment in addiction neuroimaging, clinical outcomes for individuals with substance use and behavioural addictions remain poor. Only 1.8% of people with substance use disorders receive effective treatment, highlighting a major disconnect between mechanistic understanding and clinical utility. This paper calls for a reorientation of...

Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials

Journal of Clinical Medicine December 29, 2025 Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al. 2 citations

Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...

Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)

Psychiatry Research December 29, 2025 Omer A. Syed, Sean M. Nestor, Muhammad Ishrat Husain et al. 1 citation

Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile within certain clinical populations, little empirical research has explored safety of psychedelic use within real-world samples. Using the World Health Organization (WHO) VigiBase, a comprehensive global pharmacovigilance database with voluntary...

A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Psychedelic Medicine December 26, 2025 Rhianna Rich, Kelsey T. Laird, Prabha Siddarth et al.

Background: Psychedelic-assisted psychotherapy has shown promising results for treating alcohol use disorder (AUD) and other mental health conditions. Although the precise mechanisms of psychedelic therapies remain unclear, many studies report increased feelings of connectedness following psychedelic experiences. Specifically, both nature relatedness (one’s subjective sense of being connected...